Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies (Q48199074)

9 February 2018

title

Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies (English)

1 reference

9 February 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29024301%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29024301%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Michael D Jain

1 reference

9 February 2018

publication date

11 October 2017

1 reference

9 February 2018

published in

Stem Cells

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29024301%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29024301%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29024301%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

36-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29024301%20AND%20SRC:MED&resulttype=core&format=json

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

3 June 2020

cites work

1 reference

Targeting tumours with genetically enhanced T lymphocytes

21 January 2018

1 reference

Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes

21 January 2018

1 reference

21 January 2018

The B7-CD28 superfamily

1 reference

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

21 January 2018

1 reference

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

21 January 2018

1 reference

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

21 January 2018

1 reference

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

21 January 2018

1 reference

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

21 January 2018

1 reference

Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer

21 January 2018

1 reference

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

21 January 2018

1 reference

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

21 January 2018

1 reference

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

21 January 2018

1 reference

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

21 January 2018

1 reference

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

21 January 2018

1 reference

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

21 January 2018

1 reference

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

21 January 2018

1 reference

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment

21 January 2018

1 reference

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

21 January 2018

1 reference

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

21 January 2018

1 reference

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

21 January 2018

1 reference

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

21 January 2018

1 reference

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia

21 January 2018

1 reference

PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses

21 January 2018

1 reference

Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.

21 January 2018

1 reference

Chimeric Antigen Receptor T Cells in Hematologic Malignancies

21 January 2018

1 reference

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

21 January 2018

1 reference

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

21 January 2018

1 reference

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

21 January 2018

1 reference

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells

21 January 2018

1 reference

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

21 January 2018

1 reference

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

21 January 2018

1 reference

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy

21 January 2018

1 reference

CD19, from bench to bedside

21 January 2018

1 reference

An antibody-deficiency syndrome due to mutations in the CD19 gene

21 January 2018

1 reference

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy

21 January 2018

1 reference

Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment

21 January 2018

1 reference

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

21 January 2018

1 reference

Toxicities of chimeric antigen receptor T cells: recognition and management

21 January 2018

1 reference

CAR-T's forge ahead, despite Juno deaths

21 January 2018

1 reference

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis

21 January 2018

1 reference

Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?

21 January 2018

1 reference

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

21 January 2018

1 reference

Management of Relapsed Diffuse Large B-cell Lymphoma

21 January 2018

1 reference

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

21 January 2018

1 reference

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

21 January 2018

1 reference

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

21 January 2018

1 reference

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymp

21 January 2018

1 reference

How to manage mantle cell lymphoma.

21 January 2018

1 reference

Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.

21 January 2018

1 reference

Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma

21 January 2018

1 reference

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

21 January 2018

1 reference

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

21 January 2018

1 reference

Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.

21 January 2018

1 reference

CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.

21 January 2018

1 reference

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

21 January 2018

1 reference

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

21 January 2018

1 reference

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/STEM.2715

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29024301%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29024301%20AND%20SRC:MED&resulttype=core&format=json